-
公开(公告)号：US20220105151A1
公开(公告)日：2022-04-07
申请号：US17495556
申请日：2021-10-06
发明人： Peter S. N. Rowe
摘要： A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and/or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia.
-
公开(公告)号：US20220073999A1
公开(公告)日：2022-03-10
申请号：US17514724
申请日：2021-10-29
发明人： Mei He
IPC分类号： C12Q1/6886 , A61K47/69 , G01N33/574 , G01N33/543 , B03C1/015 , B03C1/30 , B01L3/00 , A61K49/00
摘要： Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
-
公开(公告)号：US20220056002A1
公开(公告)日：2022-02-24
申请号：US17416172
申请日：2019-12-20
IPC分类号： C07D311/16 , G01N33/547
摘要： A photocleavable heterobifunctional linker can include a structure of Formula (A) wherein coumarin is any coumarin or coumarin derivative; R, R9, and R10 are each independently a chemical moiety; R1 is a hydrogen, protecting group, leaving group, substrate, or capture entity; R2 is a hydrogen, hydroxyl, halide, alkoxy, anhydride, amino, protecting group, leaving group, substrate, or capture entity; L1 is a sub-linker; and L2 is a sub-linker. A capture device can include the photocleavable bifunctional linker having a structure of Formula (A) as provide herein, wherein R1 is a substrate. A method of capturing a target substance can include: providing the capture device having the photocleavable bifunctional linker with the structure of Formula (A) and contacting a target substance to the capture moiety such that the target substance is captured. Irradiating the linker with light can cleave the linker, thereby releasing the target substance from the substrate.
-
公开(公告)号：US20220054255A1
公开(公告)日：2022-02-24
申请号：US17517027
申请日：2021-11-02
发明人： Michael Detamore , Lindsey Ott , Robert Weatherly
摘要： An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.
-
公开(公告)号：US20220008474A1
公开(公告)日：2022-01-13
申请号：US17488702
申请日：2021-09-29
发明人： Amara Seng , Ryan Fischer , Thomas Yankee , Mary Markiewicz , John Szarejko
IPC分类号： A61K35/17 , C12N15/86 , C12N5/0783
摘要： Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+ Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
-
公开(公告)号：US11162143B2
公开(公告)日：2021-11-02
申请号：US17236561
申请日：2021-04-21
发明人： Mei He
IPC分类号： G01N27/00 , B03C5/00 , G01N27/12 , C12Q1/6886 , A61K47/69 , G01N33/574 , G01N33/543 , B03C1/015 , B03C1/30 , B01L3/00 , A61K49/00
摘要： Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
-
公开(公告)号：US11160832B2
公开(公告)日：2021-11-02
申请号：US16924950
申请日：2020-07-09
发明人： Amara Seng , Ryan Fischer , Thomas Yankee , Mary Markiewicz , John Szarejko
IPC分类号： C12N5/00 , A61K35/17 , C12N15/86 , C12N5/0783
摘要： Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
-
公开(公告)号：US20210322569A1
公开(公告)日：2021-10-21
申请号：US17354514
申请日：2021-06-22
发明人： Steven R. BUCHMAN , Mark COHEN , Alexis DONNEYS , Noah NELSON , Laird FORREST , Ti ZHANG , Qiuhong YANG
IPC分类号： A61K47/69 , A61K9/51 , A61L27/50 , A61K47/61 , A61P19/00 , A61P19/08 , A61K31/16 , A61L27/20 , A61L27/54 , A61L27/58
摘要： The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).
-
公开(公告)号：US20200101132A1
公开(公告)日：2020-04-02
申请号：US16444829
申请日：2019-06-18
发明人： Peter S. N. Rowe , Aline Martin , Nicolae Valentin David , M. Laird Forrest , Kenneth Ryan Moulder , Shuang Cai , Daniel J. Aires
IPC分类号： A61K38/16 , A61K9/00 , A61K9/107 , A61K9/127 , A61K8/64 , A61Q7/00 , A61K8/14 , A61K45/06 , A61K31/506 , A61K31/58 , A61K47/10 , A61K47/69
摘要： A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.
-
公开(公告)号：US20190314554A1
公开(公告)日：2019-10-17
申请号：US16428534
申请日：2019-05-31
发明人： Michael DETAMORE , Emily BECK , Stevin GEHRKE , Cory BERKLAND
摘要： An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.
-
-
-
-
-
-
-
-
-
搜索结果
127 条记录 (耗时 0.029 秒)